FDA wants to relax approval process for Alzheimer's drugs

March 14, 2013
FDA wants to relax approval process for alzheimer's drugs
Agency points to need for medications that could prevent, slow disease in an aging population.

(HealthDay)—In an effort to quickly develop drugs that could prevent or slow Alzheimer's, the U.S. Food and Drug Administration said it plans to relax the approval process for experimental medications for the memory-robbing disease.

In a proposal published online in the March 14 issue of the New England Journal of Medicine, the FDA said clinical trials of people in the early stages of Alzheimer's would only need to show improvement in tests of thinking and memory. Among these patients, who are only starting to show subtle mental declines, improvements in daily functioning would not have to be seen, The New York Times reported.

The FDA's goal is to speed development of drugs to treat a disease that has no cure, so that the millions of at risk for Alzheimer's might be able to prevent or slow the . The FDA is taking comments on the proposal, and will possibly make revisions, but the plan is going forward, agency officials said.

Drug companies would still be required to do post-marketing studies on any approved drugs, to confirm their benefits and safeguard against any potential harms from long-term use of these medications.

More than 5 million Americans are living with Alzheimer's, according to the Alzheimer's Association, which translates into one in eight seniors.

And those numbers are expected to swell in the next 20 years, according to the U.S. National Institute on Aging (NIA). The 65-and-older population is expected to double to about 72 million in two decades, and the number of people with Alzheimer's doubles for every five-year interval past age 65, studies have shown. The number of the very elderly, age 85 and older, is estimated to triple by 2050, the NIA added.

Explore further: Researchers investigating potential drug for treatement of Alzheimer's disease

More information: For more on Alzheimer's disease, go to the U.S. National Library of Medicine.

Related Stories

Researchers investigating potential drug for treatement of Alzheimer's disease

August 31, 2012
A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology ...

U.S. launches extensive Alzheimer's studies

January 14, 2013
(HealthDay)—Four U.S. government-funded clinical trials will search for new therapies for Alzheimer's disease.

Alzheimer's drug fails study but flashes potential

August 24, 2012
(AP)—An Alzheimer's treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases of the mind-robbing condition that is notoriously ...

Trial set to see if drug can prevent Alzheimer's

May 16, 2012
(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

Lilly drug chosen for Alzheimer's prevention study (Update)

January 18, 2013
Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.

Number of people with Alzheimer's disease may triple by 2050

February 6, 2013
The number of people with Alzheimer's disease is expected to triple in the next 40 years, according to a new study published in the February 6, 2013, online issue of Neurology, the medical journal of the American Academy ...

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.